Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Assets Average (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Assets Average for 10 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 10.49% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 10.49% decrease, with the full-year FY2025 number at $1.5 billion, up 1.37% from a year prior.
  • Assets Average was $1.4 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.7 billion in Q1 2021 to a low of $1.2 billion in Q3 2025.
  • A 5-year average of $1.4 billion and a median of $1.5 billion in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 41.74% in 2021, then fell 20.91% in 2025.
  • Ultragenyx Pharmaceutical's Assets Average stood at $1.5 billion in 2021, then increased by 5.21% to $1.6 billion in 2022, then decreased by 13.74% to $1.4 billion in 2023, then rose by 11.44% to $1.5 billion in 2024, then decreased by 10.49% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Assets Average are $1.4 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.3 billion (Q2 2025).